Circulating Tissue Polypeptide-Specific Antigen in Pre-Diagnostic Pancreatic Cancer Samples

Early detection of pancreatic ductal adenocarcinoma (PDAC) is challenging, and late diagnosis partly explains the low 5-year survival. Novel and sensitive biomarkers are needed to enable early PDAC detection and improve patient outcomes. Tissue polypeptide specific antigen (TPS) has been studied as...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Emmy Borgmästars, Erik Lundberg, Daniel Öhlund, Hanna Nyström, Oskar Franklin, Christina Lundin, Pär Jonsson, Malin Sund
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	TPS pancreatic ductal adenocarcinoma circulating biomarkers early detection pre-diagnostic cohort Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e121675efd024bdaa6885df50ba5efb1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e121675efd024bdaa6885df50ba5efb1
record_format	dspace
spelling	oai:doaj.org-article:e121675efd024bdaa6885df50ba5efb12021-11-11T15:28:17ZCirculating Tissue Polypeptide-Specific Antigen in Pre-Diagnostic Pancreatic Cancer Samples10.3390/cancers132153212072-6694https://doaj.org/article/e121675efd024bdaa6885df50ba5efb12021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5321https://doaj.org/toc/2072-6694Early detection of pancreatic ductal adenocarcinoma (PDAC) is challenging, and late diagnosis partly explains the low 5-year survival. Novel and sensitive biomarkers are needed to enable early PDAC detection and improve patient outcomes. Tissue polypeptide specific antigen (TPS) has been studied as a biomarker in PDAC diagnostics, and it has previously been shown to reflect clinical status better than the ‘golden standard’ biomarker carbohydrate antigen 19-9 (CA 19-9) that is most widely used in the clinical setting. In this cross-sectional case-control study using pre-diagnostic plasma samples, we aim to evaluate the potential of TPS as a biomarker for early PDAC detection. Furthermore, in a subset of individuals with multiple samples available at different time points before diagnosis, a longitudinal analysis was used. We assessed plasma TPS levels using enzyme-linked immunosorbent assay (ELISA) in 267 pre-diagnostic PDAC plasma samples taken up to 18.8 years before clinical PDAC diagnosis and in 320 matched healthy controls. TPS levels were also assessed in 25 samples at PDAC diagnosis. Circulating TPS levels were low both in pre-diagnostic samples of future PDAC patients and in healthy controls, whereas TPS levels at PDAC diagnosis were significantly increased (odds ratio 1.03; 95% confidence interval: 1.01–1.05) in a logistic regression model adjusted for age. In conclusion, TPS levels increase late in PDAC progression and hold no potential as a biomarker for early detection.Emmy BorgmästarsErik LundbergDaniel ÖhlundHanna NyströmOskar FranklinChristina LundinPär JonssonMalin SundMDPI AGarticleTPSpancreatic ductal adenocarcinomacirculating biomarkersearly detectionpre-diagnostic cohortNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5321, p 5321 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	TPS pancreatic ductal adenocarcinoma circulating biomarkers early detection pre-diagnostic cohort Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	TPS pancreatic ductal adenocarcinoma circulating biomarkers early detection pre-diagnostic cohort Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Emmy Borgmästars Erik Lundberg Daniel Öhlund Hanna Nyström Oskar Franklin Christina Lundin Pär Jonsson Malin Sund Circulating Tissue Polypeptide-Specific Antigen in Pre-Diagnostic Pancreatic Cancer Samples
description	Early detection of pancreatic ductal adenocarcinoma (PDAC) is challenging, and late diagnosis partly explains the low 5-year survival. Novel and sensitive biomarkers are needed to enable early PDAC detection and improve patient outcomes. Tissue polypeptide specific antigen (TPS) has been studied as a biomarker in PDAC diagnostics, and it has previously been shown to reflect clinical status better than the ‘golden standard’ biomarker carbohydrate antigen 19-9 (CA 19-9) that is most widely used in the clinical setting. In this cross-sectional case-control study using pre-diagnostic plasma samples, we aim to evaluate the potential of TPS as a biomarker for early PDAC detection. Furthermore, in a subset of individuals with multiple samples available at different time points before diagnosis, a longitudinal analysis was used. We assessed plasma TPS levels using enzyme-linked immunosorbent assay (ELISA) in 267 pre-diagnostic PDAC plasma samples taken up to 18.8 years before clinical PDAC diagnosis and in 320 matched healthy controls. TPS levels were also assessed in 25 samples at PDAC diagnosis. Circulating TPS levels were low both in pre-diagnostic samples of future PDAC patients and in healthy controls, whereas TPS levels at PDAC diagnosis were significantly increased (odds ratio 1.03; 95% confidence interval: 1.01–1.05) in a logistic regression model adjusted for age. In conclusion, TPS levels increase late in PDAC progression and hold no potential as a biomarker for early detection.
format	article
author	Emmy Borgmästars Erik Lundberg Daniel Öhlund Hanna Nyström Oskar Franklin Christina Lundin Pär Jonsson Malin Sund
author_facet	Emmy Borgmästars Erik Lundberg Daniel Öhlund Hanna Nyström Oskar Franklin Christina Lundin Pär Jonsson Malin Sund
author_sort	Emmy Borgmästars
title	Circulating Tissue Polypeptide-Specific Antigen in Pre-Diagnostic Pancreatic Cancer Samples
title_short	Circulating Tissue Polypeptide-Specific Antigen in Pre-Diagnostic Pancreatic Cancer Samples
title_full	Circulating Tissue Polypeptide-Specific Antigen in Pre-Diagnostic Pancreatic Cancer Samples
title_fullStr	Circulating Tissue Polypeptide-Specific Antigen in Pre-Diagnostic Pancreatic Cancer Samples
title_full_unstemmed	Circulating Tissue Polypeptide-Specific Antigen in Pre-Diagnostic Pancreatic Cancer Samples
title_sort	circulating tissue polypeptide-specific antigen in pre-diagnostic pancreatic cancer samples
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/e121675efd024bdaa6885df50ba5efb1
work_keys_str_mv	AT emmyborgmastars circulatingtissuepolypeptidespecificantigeninprediagnosticpancreaticcancersamples AT eriklundberg circulatingtissuepolypeptidespecificantigeninprediagnosticpancreaticcancersamples AT danielohlund circulatingtissuepolypeptidespecificantigeninprediagnosticpancreaticcancersamples AT hannanystrom circulatingtissuepolypeptidespecificantigeninprediagnosticpancreaticcancersamples AT oskarfranklin circulatingtissuepolypeptidespecificantigeninprediagnosticpancreaticcancersamples AT christinalundin circulatingtissuepolypeptidespecificantigeninprediagnosticpancreaticcancersamples AT parjonsson circulatingtissuepolypeptidespecificantigeninprediagnosticpancreaticcancersamples AT malinsund circulatingtissuepolypeptidespecificantigeninprediagnosticpancreaticcancersamples
_version_	1718435275411030016

Circulating Tissue Polypeptide-Specific Antigen in Pre-Diagnostic Pancreatic Cancer Samples

Ejemplares similares